These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 18585795)

  • 1. Closing the door on flaviviruses: entry as a target for antiviral drug design.
    Perera R; Khaliq M; Kuhn RJ
    Antiviral Res; 2008 Oct; 80(1):11-22. PubMed ID: 18585795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein.
    de Wispelaere M; Lian W; Potisopon S; Li PC; Jang J; Ficarro SB; Clark MJ; Zhu X; Kaplan JB; Pitts JD; Wales TE; Wang J; Engen JR; Marto JA; Gray NS; Yang PL
    Cell Chem Biol; 2018 Aug; 25(8):1006-1016.e8. PubMed ID: 29937406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses.
    Kampmann T; Yennamalli R; Campbell P; Stoermer MJ; Fairlie DP; Kobe B; Young PR
    Antiviral Res; 2009 Dec; 84(3):234-41. PubMed ID: 19781577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of viral and cellular factors on flavivirus entry.
    Cordero-Rivera CD; De Jesús-González LA; Osuna-Ramos JF; Palacios-Rápalo SN; Farfan-Morales CN; Reyes-Ruiz JM; Del Ángel RM
    Curr Opin Virol; 2021 Aug; 49():164-175. PubMed ID: 34171540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flaviviruses: braking the entering.
    Pierson TC; Kielian M
    Curr Opin Virol; 2013 Feb; 3(1):3-12. PubMed ID: 23352692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy in Vivo.
    Li PC; Jang J; Hsia CY; Groomes PV; Lian W; de Wispelaere M; Pitts JD; Wang J; Kwiatkowski N; Gray NS; Yang PL
    ACS Infect Dis; 2019 Mar; 5(3):460-472. PubMed ID: 30608640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule inhibitors possibly targeting the rearrangement of Zika virus envelope protein.
    Sharma N; Prosser O; Kumar P; Tuplin A; Giri R
    Antiviral Res; 2020 Oct; 182():104876. PubMed ID: 32783901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unified route for flavivirus structures uncovers essential pocket factors conserved across pathogenic viruses.
    Hardy JM; Newton ND; Modhiran N; Scott CAP; Venugopal H; Vet LJ; Young PR; Hall RA; Hobson-Peters J; Coulibaly F; Watterson D
    Nat Commun; 2021 Jun; 12(1):3266. PubMed ID: 34075032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel target sites and an inhibitor of the dengue virus E protein.
    Yennamalli R; Subbarao N; Kampmann T; McGeary RP; Young PR; Kobe B
    J Comput Aided Mol Des; 2009 Jun; 23(6):333-41. PubMed ID: 19241120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capturing a flavivirus pre-fusion intermediate.
    Kaufmann B; Chipman PR; Holdaway HA; Johnson S; Fremont DH; Kuhn RJ; Diamond MS; Rossmann MG
    PLoS Pathog; 2009 Nov; 5(11):e1000672. PubMed ID: 19956725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein.
    Lian W; Jang J; Potisopon S; Li PC; Rahmeh A; Wang J; Kwiatkowski NP; Gray NS; Yang PL
    ACS Infect Dis; 2018 Sep; 4(9):1395-1406. PubMed ID: 30027735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular Targets for the Treatment of Flavivirus Infections.
    Zakaria MK; Carletti T; Marcello A
    Front Cell Infect Microbiol; 2018; 8():398. PubMed ID: 30483483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide inhibitors of dengue virus and West Nile virus infectivity.
    Hrobowski YM; Garry RF; Michael SF
    Virol J; 2005 Jun; 2():49. PubMed ID: 15927084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry.
    Pascual MJ; Merwaiss F; Leal E; Quintana ME; Capozzo AV; Cavasotto CN; Bollini M; Alvarez DE
    Antiviral Res; 2018 Jan; 149():179-190. PubMed ID: 29031833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and functionality in flavivirus NS-proteins: perspectives for drug design.
    Bollati M; Alvarez K; Assenberg R; Baronti C; Canard B; Cook S; Coutard B; Decroly E; de Lamballerie X; Gould EA; Grard G; Grimes JM; Hilgenfeld R; Jansson AM; Malet H; Mancini EJ; Mastrangelo E; Mattevi A; Milani M; Moureau G; Neyts J; Owens RJ; Ren J; Selisko B; Speroni S; Steuber H; Stuart DI; Unge T; Bolognesi M
    Antiviral Res; 2010 Aug; 87(2):125-48. PubMed ID: 19945487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of Baculovirus-Expressed VLPs Induced Syncytial Formation Assay for Flavivirus Antiviral Screening.
    Dai S; Zhang Y; Zhang T; Zhang B; Wang H; Deng F
    Viruses; 2018 Jul; 10(7):. PubMed ID: 29997331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus.
    Anasir MI; Ramanathan B; Poh CL
    Viruses; 2020 Mar; 12(4):. PubMed ID: 32225021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flavivirus structural heterogeneity: implications for cell entry.
    Rey FA; Stiasny K; Heinz FX
    Curr Opin Virol; 2017 Jun; 24():132-139. PubMed ID: 28683393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A structural perspective of the flavivirus life cycle.
    Mukhopadhyay S; Kuhn RJ; Rossmann MG
    Nat Rev Microbiol; 2005 Jan; 3(1):13-22. PubMed ID: 15608696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of flavivirus membrane fusion.
    Stiasny K; Fritz R; Pangerl K; Heinz FX
    Amino Acids; 2011 Nov; 41(5):1159-63. PubMed ID: 19882217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.